Literature DB >> 4055164

Regimen for the control of blood pressure and symptoms during clonidine withdrawal.

B C Campbell, J L Reid.   

Abstract

Abrupt withdrawal of the centrally-acting antihypertensive agent, clonidine, is associated with a high incidence of rebound hypertension and tachycardia, with symptoms of sympathetic overactivity and increased catecholamine excretion. Gradual clonidine withdrawal has been recommended, but does not always avoid the reaction. A regimen is described comprising high doses of the alpha 1-adrenoceptor antagonist, prazosin, the cardioselective beta-blocker, atenolol, and chlordiazepoxide, specifically designed to counter both central and peripheral effects of sudden withdrawal of a central alpha 2-adrenoceptor agonist. This combination was completely successful in preventing the haemodynamic and symptomatic features of clonidine withdrawal in eight hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4055164

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  4 in total

1.  Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses.

Authors:  N J Sarlis; O Caticha; J L Anderson; C Kablitz; F S Shihab
Journal:  Clin Auton Res       Date:  1996-04       Impact factor: 4.435

Review 2.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

3.  Use of Prazosin for Pediatric Post-Traumatic Stress Disorder With Nightmares and/or Sleep Disorder: Case Series of 18 Patients Prospectively Assessed.

Authors:  Vladimir Ferrafiat; Maryam Soleimani; Boris Chaumette; Audrey Martinez; Jean-Marc Guilé; Brooks Keeshin; Priscille Gerardin
Journal:  Front Psychiatry       Date:  2020-07-22       Impact factor: 4.157

4.  Use of Prazosin for Pediatric PTSD-Associated Nightmares and Sleep Disturbances: A Retrospective Chart Review.

Authors:  Brooks R Keeshin; Qian Ding; Angela P Presson; Steven J Berkowitz; Jeffrey R Strawn
Journal:  Neurol Ther       Date:  2017-07-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.